Enliven Therapeutics, Inc. (ELVN)
NASDAQ: ELVN · Real-Time Price · USD
40.17
+0.54 (1.36%)
At close: May 19, 2026, 4:00 PM EDT
39.00
-1.17 (-2.91%)
After-hours: May 19, 2026, 7:06 PM EDT
Enliven Therapeutics Employees
Enliven Therapeutics had 61 employees as of March 31, 2026. The number of employees decreased by 4 or -6.15% compared to the same quarter last year.
Employees
61
Change
-4
Growth
-6.15%
Revenue / Employee
n/a
Profits / Employee
-$1,619,295
Market Cap
2.45B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2026 | 61 | -4 | -6.15% |
| Dec 31, 2025 | 60 | -2 | -3.23% |
| Sep 30, 2025 | 65 | 8 | 14.04% |
| Jun 30, 2025 | 63 | 11 | 21.15% |
| Mar 31, 2025 | 65 | 15 | 30.00% |
| Dec 31, 2024 | 62 | 16 | 34.78% |
| Sep 30, 2024 | 57 | 13 | 29.55% |
| Jun 30, 2024 | 52 | 15 | 40.54% |
| Mar 31, 2024 | 50 | 21 | 72.41% |
| Dec 31, 2023 | 46 | 17 | 58.62% |
| Sep 30, 2023 | 44 | 20 | 83.33% |
| Jun 30, 2023 | 37 | 13 | 54.17% |
| Mar 31, 2023 | 29 | - | - |
| Sep 30, 2022 | 24 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Ultragenyx Pharmaceutical | 1,371 |
| Tarsus Pharmaceuticals | 370 |
| Arcutis Biotherapeutics | 354 |
| Vera Therapeutics | 249 |
| Celldex Therapeutics | 198 |
| Relay Therapeutics | 193 |
| Immunome | 177 |
| Disc Medicine | 154 |
ELVN News
- 7 days ago - Enliven to presents Phase 1 clinical trial data for ELVN-100 at EHA Congress - TheFly
- 7 days ago - Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CML - PRNewsWire
- 7 days ago - Guggenheim starts Enliven with Buy on leukemia opportunity - TheFly
- 8 days ago - Enliven initiated with a Buy at Guggenheim - TheFly
- 11 days ago - Enliven price target raised to $59 from $41 at Goldman Sachs - TheFly
- 12 days ago - Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update - PRNewsWire
- 12 days ago - Enliven Therapeutics Quarterly report: Q1 2026 - Filings
- 12 days ago - Enliven Therapeutics Earnings release: Q1 2026 - Filings